Regent Pacific Group Limited announced several key updates of Fortacin™/Senstend™, the first prescription solution to premature ejaculation (PE) that does not act on the central nervous system, in China and the United States respectively. Regent Pacific received USD 0.72 million (approximately HKD 5.62 million) from its commercial strategic partner in China -Wanbang Pharmaceutical Marketing and Distribution Co. Ltd. ("Wanbang Pharmaceutical"), a wholly controlled company of Shanghai Fosun Pharma to seek marketing approval of Senstend™ (the marketing name of Fortacin™ in China) in China on 29 December 2020. The Clinical Trial Approval ("CTA") of Senstend™ will be reviewed by the National Medical Products Administration ("NMPA") and is expected to be obtained from the Center of Drug Evaluation by the end of first quarter of 2021. Upon the successful approval from NMPA to commence the clinical trial, Regent Pacific will receive a payment of USD 3.20 million (approximately HKD 24.96 million) from Wanbang Pharmaceutical. Regent Pacific will receive USD 5 million (approximately HKD 39 million) from Wanbang Pharmaceutical if the clinical study tentatively to be started in April/May 2021 meets its endpoints of determining the effects of Senstend™ on the Index of Premature Ejaculation (IPE) and the Intra-vaginal Ejaculation Latency Time (IELT) and to evaluate the safety and tolerability of Senstend™ in Premature Ejaculation subjects and their sexual partners, together with an import licence for Senstend™ granted by NMPA. Regent Pacific will also receive USD 2 million (approximately HKD 15.6 million) upon the first commercial sale of Senstend™ in China from Wanbang Pharmaceutical with tiered percentage royalties on net sales, ranging from low to the high teens from first commercial sale.